Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases affecting bone health and blood vessel function, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's CEO and Chairman, Doug Treco, Ph.D., will engage in a fireside chat scheduled for Monday, April 7, 2025, from 2:15-2:55pm ET. Investors and interested parties can access the live webcast through the Investor Relations section of Inozyme's website under events. A replay will be available for a time following the presentation.

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, from 2:15-2:55pm ET.

A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

About Inozyme Pharma

Inozyme Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to restore PPi and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the PPi-Adenosine Pathway contribute to disease pathology. Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions.

For more information, please visit www.inozyme.com and follow us on LinkedIn, X, and Facebook.

Contacts

Investors:
Inozyme Pharma
Stefan Riley, Director of IR and Corporate Communications
(617) 461-2442
stefan.riley@inozyme.com

Media:
Biongage Communications
Todd Cooper
(617) 840-1637
todd@biongage.com

FAQ

When is Inozyme Pharma (INZY) presenting at the Needham Healthcare Conference 2025?

Inozyme Pharma will present on Monday, April 7, 2025, from 2:15-2:55pm ET during a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.

How can investors watch Inozyme Pharma's (INZY) Needham Conference presentation?

Investors can watch the live webcast through the Investor Relations section of Inozyme's website under events, where a replay will also be available.

What type of diseases does Inozyme Pharma (INZY) focus on treating?

Inozyme Pharma focuses on developing therapeutics for rare diseases that affect bone health and blood vessel function.

What is the format of Inozyme Pharma's (INZY) presentation at the Needham Conference?

The presentation will be in a fireside chat format, featuring CEO and Chairman Doug Treco, Ph.D.